Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

被引：46

作者：

Rha, S. Y. ^{[1
]}

Wyrwicz, L. S. ^{[2
]}

Weber, P. E. Y. ^{[3
]}

Bai, Y. ^{[4
]}

Ryu, M. H. ^{[5
]}

Lee, J. ^{[6
]}

Rivera, F. ^{[7
]}

Alves, G. V. ^{[8
]}

Garrido, M. ^{[9
]}

Shiu, K. -k. ^{[10
]}

Fernandez, M. Gonzalez ^{[11
]}

Li, J. ^{[12
]}

Lowery, M. ^{[13
]}

Cil, T. ^{[14
]}

Cruz, F. J. S. M. ^{[15
]}

Qin, S. ^{[16
]}

Yin, L. ^{[17
]}

Bordia, S. ^{[18
]}

Bhagia, P. ^{[18
]}

Oh, D-y. ^{[19
]}

机构：

[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Internal Med, Seoul, South Korea

[2] Mar Sklodowska Curie Natl Res Inst Oncol, Oncol & Radiotherapy, Warsaw, Poland

[3] Univ La Frontera, James Lind Canc Res Ctr, Internal Med, Temuco, Chile

[4] Harbin Med Univ, Canc Hosp, Gastrointestinal Oncol, Harbin, Peoples R China

[5] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Samsung Med Ctr SMC, Hematol & Oncol, Sch Med, Seoul, South Korea

[7] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

[8] Hosp Nossa Senhora Conceicao, Med Oncol, Porto Alegre, Brazil

[9] Univ Mayor, Oncol, Santiago, Chile

[10] Univ Coll Hosp NHS Fdn Trust, Oncol, London, England

[11] IMAT Oncomed, Monteria, Colombia

[12] Tongji Univ, Shanghai East Hosp, Med Oncol, Sch Med, Shanghai, Peoples R China

[13] Trinity St James Canc Inst, Med Oncol, Dublin, Ireland

[14] Hlth & Sci Univ, Adana City Hosp, Med Oncol, Adana, Turkiye

[15] Nucleo Pesquisa & Ensino Rede Sao Camilo, Med Oncol, Sao Paulo, Brazil

[16] Canc Ctr Peoples Liberat Army, Med Oncol, Nanjing, Peoples R China

[17] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA

[18] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[19] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期

关键词：

D O I：

10.1016/j.annonc.2023.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：319 / 320

页数：2

共 50 条

[41] Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Shitara, K.
Rha, S. Y.
Wyrwicz, L. S.
Oshima, T.
Karaseva, N.
Osipov, M.
Yasui, H.
Yabusaki, H.
Afanasyev, S.
Park, Y-K.
Al-Batran, S-E.
Yoshikawa, T.
Weber, P. E. Yanez
Di Bartolomeo, M.
Lonardi, S.
Fang, X.
Shih, C-S.
Bhagia, P.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2024, 35 : S213 - S213
[42] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Kowalski, Dariusz
Breder, Valeriy Vladimirovich
Pollock, Theodore
Reguart, Noemi
Houghton, Baerin
Quantin, Xavier
Keller, Steven M.
Liu, Hong
Piperdi, Bilal
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43] KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David
Hyung, Woo Jin
Strong, Vivian
Goetze, Thorsten
Yoshikawa, Takaki
Tang, Laura
Sun, Linda
Hasan, Aisha
Koshiji, Minori
Shitara, Kohei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[44] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Xu, R-H.
Ajani, J. A.
Al-Batran, S-E.
Bang, Y-J.
Catenacci, D.
Enzinger, P. C.
Ilson, D. H.
Kim, S.
Lordick, F.
Shitara, K.
van Cutsem, E.
Arozullah, A.
Park, J. W.
Shah, M. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
[45] Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
Kato, K.
Shah, M. A.
Enzinger, P. C.
Bennouna, J.
Shen, L.
Adenis, A.
Sun, J-M.
Cho, B. C.
Ozguroglu, M.
Kojima, T.
Kostorov, V.
Hierro, C.
Zhu, Y.
Shah, S.
Bhagia, P.
Doi, T.
ANNALS OF ONCOLOGY, 2018, 29
[46] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Shitara, K.
Ozguroglu, M.
Bang, Y. J.
Di Bartolomeo, M.
Mandala, M.
Ryu, M. H.
Fornaro, L.
Olesinski, T.
Caglevic, C.
Chung, H.
Muro, K.
Gokkurt, E.
Mansoor, W.
McDermott, R.
Schacham-Shmueli, E.
Chen, X.
Kang, S. P.
Mayo, C.
Ohtsu, A.
Fuchs, C.
ANNALS OF ONCOLOGY, 2018, 29
[47] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
Lang, Wenwang
Deng, Lian
Lu, Meijun
Ouyang, Ming
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
[48] Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Lee, Keun-Wook
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo R.
Chao, Joseph
Wainberg, Zev A.
Cao, Z. Alexander
Aurora-Garg, Deepti
Kobie, Julie
Cristescu, Razvan
Bhagia, Pooja
Shah, Sukrut
Tabernero, Josep
Shitara, Kohei
Wyrwicz, Lucjan
CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3489 - 3498
[49] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Kato, Ken
Shah, Manish A.
Enzinger, Peter
Bennouna, Jaafar
Shen, Lin
Adenis, Antoine
Sun, Jong-Mu
Cho, Byoung Chul
Ozguroglu, Mustafa
Kojima, Takashi
Kostorov, Vladimir
Hierro, Cinta
Zhu, Ying
McLean, Lee Anne
Shah, Sukrut
Doi, Toshihiko
FUTURE ONCOLOGY, 2019, 15 (10) : 1057 - 1066
[50] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
Schmid, Peter
Cortes, Javier
Bergh, Jonas C. S.
Pusztai, Lajos
Denkert, Carsten
Verma, Sunil
McArthur, Heather L.
Kummel, Sherko
Ding, Yu
Karantza, Vassiliki
Dang, Thao
Dent, Rebecca Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →